Axim Financial Statements From 2010 to 2025

AXIM Stock  USD 0  0.00  0.00%   
Axim Biotechnologies financial statements provide useful quarterly and yearly information to potential Axim Biotechnologies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Axim Biotechnologies financial statements helps investors assess Axim Biotechnologies' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Axim Biotechnologies' valuation are summarized below:
Axim Biotechnologies does not presently have any fundamental signals for analysis.
Check Axim Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axim Biotechnologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Axim financial statements analysis is a perfect complement when working with Axim Biotechnologies Valuation or Volatility modules.
  
This module can also supplement various Axim Biotechnologies Technical models . Check out the analysis of Axim Biotechnologies Correlation against competitors.

Axim Biotechnologies Company Shares Outstanding Analysis

Axim Biotechnologies' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Axim Biotechnologies Shares Outstanding

    
  186.44 M  
Most of Axim Biotechnologies' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axim Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Axim Biotechnologies has 186.44 M of shares currently outstending. This is 3.27% higher than that of the Biotechnology sector and 74.48% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 67.39% higher than that of the company.

Axim Biotechnologies Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Axim Biotechnologies's current stock value. Our valuation model uses many indicators to compare Axim Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Axim Biotechnologies competition to find correlations between indicators driving Axim Biotechnologies's intrinsic value. More Info.
Axim Biotechnologies is rated fourth in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Axim Biotechnologies' earnings, one of the primary drivers of an investment's value.

About Axim Biotechnologies Financial Statements

Axim Biotechnologies investors utilize fundamental indicators, such as revenue or net income, to predict how Axim Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Axim Pink Sheet

Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.